UK expects to get 10 million doses of Pfizer/BioNTech vaccine this year
By Alistair Smout and Elizabeth Piper LONDON (Reuters) - Britain expects to have 10 million doses of Pfizer/BioNTech's candidate COVID-19 vaccine available by the end of the year, but Prime Minister Boris Johnson on Monday said there were several hurdles to go after its positive clinical trial results.
By Alistair Smout and Elizabeth Piper
LONDON (Reuters) - Britain expects to have 10 million doses of Pfizer/BioNTech's candidate COVID-19 vaccine available by the end of the year, but Prime Minister Boris Johnson on Monday said there were several hurdles to go after its positive clinical trial results.
Pfizer said its experimental COVID-19 vaccine was more than 90% effective, a big gain in the fight against a pandemic that has killed more than a million people and battered the world's economy.
Johnson said Britain had now ordered 40 million doses of the candidate vaccine developed by Pfizer Inc
Johnson has said that the prospects of a vaccine are one cause for optimism that the situation will improve by spring, but said new lockdown rules in England still needed to be obeyed even though scientific progress was on the horizon.
"We have cleared one significant hurdle but there are several more to go before we know the vaccine can be used," Johnson said, referring to the need to see safety data and for approval by regulators.
"We absolutely cannot rely on this as a solution. The biggest mistake we could make now would be to slacken our resolve at such a critical moment."
Johnson - who himself was hospitalised earlier this year after being stricken with COVID-19 - said that once the vaccine was approved, Britain would be ready to start using it. The health service woud lead a programme of distribution, with the elderly and frontline workers first in line.
"I am hopeful, but not yet certain, that we could begin to see some vaccine by Christmas," said England's Deputy Chief Medical Office Jonathan Van-Tam.
In all, the government has signed six supply deals for vaccine candidates, including Pfizer/BioNTech's and one developed by Oxford University and AstraZeneca
John Bell, regius professor of medicine at University of Oxford who sits on the government's vaccine taskforce, told BBC Radio he could not see "any reason now why we shouldn't have a handful of good vaccines available to this disease".
He added that he was "optimistic that given this result, we'll have a reasonably good chance of getting a good result as well," referring to Oxford's own late-stage trial results he said would come in "weeks not months".
Asked if life would be returning to normal by the Spring, Oxford's Bell said: "Yes, yes, yes."
"I'm probably the first guy to say that but...I will say that with some confidence."
(editing by Estelle Shirbon/Guy Faulconbridge)
This story has not been edited by Firstpost staff and is generated by auto-feed.
Find latest and upcoming tech gadgets online on Tech2 Gadgets. Get technology news, gadgets reviews & ratings. Popular gadgets including laptop, tablet and mobile specifications, features, prices, comparison.
By Jarrett Renshaw and Joseph Tanfani (Reuters) - As President Donald Trump seeks to discredit last week's election with baseless claims of voter fraud, his team has bombarded his supporters with requests for money to help pay for legal challenges to the results: “The Left will try to STEAL this election!” reads one text. But any small-dollar donations from Trump's grassroots donors won't be going to legal expenses at all, according to a Reuters review of the legal language in the solicitations
RIYADH (Reuters) - Saudi Arabia's King Salman bin Abdulaziz urged the world on Thursday to take "a decisive stance" to address efforts by Iran to develop nuclear and ballistic missile programs, in an annual address to the top government advisory body. "The kingdom stresses the dangers of Iran's regional project, its interference in other countries, its fostering of terrorism, its fanning the flames of sectarianism ..
By Jose Sanchez BELIZE CITY (Reuters) - Belizeans headed to the polls on Wednesday to replace a veteran prime minister, with many in the tiny Central American country saying they were ready for change to repair an economy battered by pandemic-driven shutdowns. Dean Barrow, the outgoing prime minister, ran Belize for more than a dozen years.